FDA Adds Warning on NAION Risk with GLP-1 Receptor Agonists
November 10, 2026
FDA is adding a warning on NAION risk with GLP-1 receptor agonists to the labels of every product in the class. The eye condition is rare, but it can cause sudden, painless vision loss in one eye, including permanent loss.
The change follows a meta-analysis of 126 randomized, controlled trials that included 134,253 patients and 288,879 person-years of exposure. FDA counted 15 probable NAION events, 10 in patients on a GLP-1 receptor agonist and 5 on placebo. The incidence was 6.4 events per 100,000 person-years on the drugs, against 3.8 events per 100,000 person-years in comparator-treated patients.
What FDA found on NAION risk with GLP-1 receptor agonists
FDA also analyzed a Sentinel cohort of adults with type 2 diabetes who started a GLP-1 receptor agonist, an SGLT-2 inhibitor or a DPP-4 inhibitor between 2019 and 2024. Compared with DPP-4 inhibitors, the hazard ratio was 1.43 (95% CI 1.02, 2.01). Compared with SGLT-2 inhibitors, it was 1.19 (95% CI 0.91, 1.54), which is not statistically significant. NAION cases have been reported for every GLP-1 receptor agonist on the US market.
Patients should report sudden, painless vision loss, blurred or missing areas of vision, or distorted colors to their clinician right away. Suspected NAION should be referred to an ophthalmologist, and cases can be reported through MedWatch.
Why it matters
Published literature puts background NAION incidence at 2.3 to 10.2 cases per 100,000 adults a year over age 50, so the drug-associated rate of 6.4 falls inside that range. The gap between the two arms is 2.6 events per 100,000 person-years, by our calculation, and the pooled count is only 15 events. The label advises considering a stop after a NAION event, unless the benefit clearly outweighs the risk. The European Medicines Agency had earlier opened its own review of the semaglutide NAION signal. Syenza News has also reported that adverse reaction reports in Portugal rise with GLP-1 use.
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.